Patent
Pyrollidine-based compounds
Li Chen,Eric Dale Jones,Dawei Ma,Dean Baylis,Ben Li,Jonathan Coates,Xin Xie,David Ian Rhodes,Renhai Chen,John Deadman +9 more
- 18 Jan 2008
12
TL;DR: The present invention discloses the compounds of formula (I ) or a pharmaceutically acceptable derivative, salt or prodrug thereof, which can inhibit HIV replication as mentioned in this paper. But the present invention does not reveal the compounds that can be used to prevent HIV replication.
read more
Abstract: The present invention discloses the compounds of formula ( I ) or a pharmaceutically acceptable derivative, salt or prodrug thereof, which can inhibit HIV replication.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Patent
Method for the synthesis of phosphorus atom modified nucleic acids
Takeshi Wada,Mamoru Shimizu +1 more
- 02 Dec 2009
TL;DR: In this paper, an asymmetric reaction of an achiral molecule comprising a chemically stable H-phophonate moiety with a nucleoside/nucleotide is described.
33
Patent
Asymmetric auxiliary group
Mamoru Shimizu,Takeshi Wada +1 more
- 12 Jul 2013
TL;DR: In this paper, the chiral reagent has following chemical formula (I): G1 and G2 are independently a hydrogen atom, a nitro group (-NO2), a halogen atom or a cyano group (-CN), a group of formula (II) or (III), or both G 1 and G 2 taken together to form a group (IV).
28
Patent
Methods for the synthesis of functionalized nucleic acids
Gregory L. Verdine,Meena,Naoki Iwamoto,David Butler +3 more
- 13 Jul 2012
TL;DR: In this paper, methods for the synthesis of derivatives of thiosulfonate reagents have been described for synthesis of phosphorothiotriesters from H- phosphonates in a stereospecific fashion.
28
Patent
Asymmetric ureas and medical uses thereof
Garcia Rubio Silvina,Claudio Pietra,Claudio Giuliano,Li Zhigang +3 more
- 23 Feb 2012
TL;DR: In this paper, the authors have disclosed compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor.
11
Patent
Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
Takefumi Gemba,Ryoichi Nagata,Ikumi Shiga +2 more
- 14 Jan 2015
TL;DR: In this paper, a chiral nucleic acid adjuvant having immunity-inducing activity and an immunity-inducible activator comprising the adjus- ture is proposed.
10
References
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements.
Jeffrey J. Hale,Richard J. Budhu,Sander G. Mills,Malcolm MacCoss,Lorraine Malkowitz,Salvatore J. Siciliano,Sandra L. Gould,Julie A. DeMartino,Martin S. Springer +8 more
TL;DR: A series of 1,3,4-trisubstituted pyrrolidines was discovered to have the ability to displace [(125)I]-MIP-1alpha from the CCR5 receptor expressed on Chinese hamster ovary (CHO) cell membranes.
52
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 4: synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIV.
Christopher L. Lynch,Jeffrey J. Hale,Richard J. Budhu,Amy Gentry,Sander G. Mills,Kevin T. Chapman,Malcolm MacCoss,Lorraine Malkowitz,Martin S. Springer,Sandra L. Gould,Julie A. DeMartino,Salvatore J. Siciliano,Margaret A. Cascieri,Anthony Carella,Gwen Carver,Karen Holmes,William A. Schleif,Renee Danzeisen,Daria J. Hazuda,Joseph Kessler,Janet Lineberger,Michael W. Miller,Emilio A. Emini +22 more
TL;DR: A series of alpha-(pyrrolidin-1-yl)acetic acids is presented as selective and potent antivirals against HIV, demonstrating reasonable in vitro properties, enhanced antiviral activities and improved pharmacokinetic profiles over pyrrolidine 1.
38
Synthesis and Biological Evaluation of 1,3,3,4‐Tetrasubstituted Pyrrolidine CCR5 Receptor Antagonists. Discovery of a Potent and Orally Bioavailable Anti‐HIV Agent
Dawei Ma,Shanghai Yu,Ben Li,Li Chen,Renhai Chen,Kunqian Yu,Linqi Zhang,Linqi Zhang,Zhiwei Chen,Dafang Zhong,Zheng Gong,Renxiao Wang,Hualiang Jiang,Gang Pei +13 more
TL;DR: Results indicated that (3R,4S)‐configuration in the series of compounds is favored for their interaction with the CCR5 receptor, and compound 30 is a promising candidate for the treatment of HIV‐1 infection.
27
Patent
Compound for treating AIDS
Chen Li Chen
- 04 Apr 2007
TL;DR: In this paper, the compound for treating AIDS, its accepted salt and its use for inhibiting HIV virus are disclosed, which can inhibit HIV virus infect human-body cell and has less by-effects.
3
Patent
Compound as CCR5 agonist
Gang Pei
- 14 Dec 2005
TL;DR: In this paper, one kind of compound was described as a CCR5 agonist and the preparation process and use of the compound as well as the medicine composition containing the compound were described.
3